
News|Articles|July 1, 2002
LABELING UPDATE: CLASS study, updated GI, CV risk info, added to celecoxib label
Safety information from the Celecoxib Long-term Arthritis Safety Study (CLASS)on GI and cardiovascular events has been included in safety labeling forcelecoxib (Celebrex, Searle).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
2
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































